Product Images Oxaliplatin

This appears to be a statistical analysis report for DFS (disease-free survival) probability. The table displays the probability (1.0 - 0.2) and the number of events (%), with the number of patients at risk for two treatment groups (AFOLFOX4 and LV5FU2). The report also includes hazard ratio and confidence interval (0.8 [0.68, 0.93]) and a stratified logrank test result (p=0.003). The x-axis represents the duration in months of DFS.*

This appears to be a survival analysis report for two different treatment groups, FOLFOX4 and LVSFU2, for patients with Dukes C stage colorectal cancer. The report gives the percentages of patients who are disease-free survival (DFS) at various time points up to 18 months, as well as the Stagel Hazard Ratio and Logrank Test p-value.*

Oxaliplatin Injection, USP is a cytotoxic agent used for intravenous therapy, and each mL contains 5mg of oxaliplatin in Water for Injection, USP. It must be diluted and the package insert should be consulted for further required dilution. It's important not to mix or add it to sodium chloride/chloride-containing solutions. It does not contain preservatives and should be protected from light, and stored at controlled room temperature, away from freezing conditions. Unused portions should be discarded, and the packaging insert describes ways of storing further diluted solutions. The vial is for a single-use only. The drug should be administered under strict medical supervision, and the package insert should be consulted for dosage and administration. The drug has a registry number, and the manufacturing company is in Rockford, IL, USA. The code number indicates its approval date.*